ArticleCarcinogenesis2025
CarD-T: an automated pipeline for the nomination and analysis of potential human carcinogens.
Article in Carcinogenesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The identification and classification of carcinogens is critical in cancer epidemiology, necessitating updated methodologies to manage the burgeoning biomedical literature. We introduce the Carcinogen Detection via Transformers (CarD-T) framework, combining transformer-based machine learning with probabilistic analysis to efficiently nominate potential carcinogens from scientific texts. Trained on 60% of established carcinogens, CarD-T correctly identifies all remaining known carcinogens and nominates ∼1600 potential new carcinogens. Comparative assessment against GPT-4 reveals CarD-T's comparable precision (0.896 versus 0.903), and superior recall (0.853 versus 0.757), implying an improved ability to nominate potential carcinogens for further evaluation. CarD-T associates each nominated entity with relevant scientific literature, allowing for additional analysis of conflicting implications over time through a Bayesian probabilistic carcinogen denomination analysis. The framework also provides rich insights into carcinogenesis associated research, revealing significant shifts in research focus on carcinogenic agents over time, from chemical carcinogens to broader categories including biological agents, environmental factors and lifestyle choices. We establish the CarD-T framework as a locally deployable, computationally inexpensive, and robust tool for identifying and nominating potential carcinogens from vast biomedical literature. This framework enhances the agility of public health responses to carcinogen identification, setting a new benchmark for automated, scalable toxicological investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.